{"id":73661,"date":"2023-08-28T15:40:35","date_gmt":"2023-08-28T10:10:35","guid":{"rendered":"http:\/\/finservwealth.com\/venus-remedies-gains-5-on-saudi-arabiaaes-marketing-approval-for-anti-coagulant-drug\/"},"modified":"2023-08-28T15:40:35","modified_gmt":"2023-08-28T10:10:35","slug":"venus-remedies-gains-5-on-saudi-arabiaaes-marketing-approval-for-anti-coagulant-drug","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/venus-remedies-gains-5-on-saudi-arabiaaes-marketing-approval-for-anti-coagulant-drug\/","title":{"rendered":"Venus Remedies gains 5% on Saudi Arabia\u00e2\u20ac\u2122s marketing approval for anti-coagulant drug"},"content":{"rendered":"<p> The company has said it has so far secured marketing authorisations from Saudi Arabia for six antibiotics meant for intensive care units and three oncology products<\/p><div id=\"finse-223990540\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/venus-remedies-gains-5saudi-arabia%C3%A2%E2%82%AC%E2%84%A2s-marketing-approval-for-anti-coagulant-drug_17221181.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The company has said it has so far secured marketing authorisations from Saudi Arabia for six antibiotics meant for intensive care units and three oncology products The company has said it has so far secured marketing authorisations from Saudi Arabia for six antibiotics meant for intensive care units and three oncology products\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/venus-remedies-gains-5saudi-arabia%C3%A2%E2%82%AC%E2%84%A2s-marketing-approval-for-anti-coagulant-drug_17221181.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> The company has said it has so far secured marketing authorisations from Saudi Arabia for six antibiotics meant for intensive care units and three oncology products<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/venus-remedies-gains-5saudi-arabia%C3%A2%E2%82%AC%E2%84%A2s-marketing-approval-for-anti-coagulant-drug_17221181.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0The company has said it has so far secured marketing authorisations from Saudi Arabia for six antibiotics meant for intensive care units and three oncology products The company has said it has so far secured marketing authorisations from Saudi Arabia for six antibiotics meant for intensive care units and three oncology products\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/venus-remedies-gains-5saudi-arabia%C3%A2%E2%82%AC%E2%84%A2s-marketing-approval-for-anti-coagulant-drug_17221181.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> The company has said it has so far secured marketing authorisations from Saudi Arabia for six antibiotics meant for intensive care units and three oncology products<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-73661","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2023\/200x200\/C\/Collage-Maker-28-Feb-2023-12_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/73661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=73661"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/73661\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=73661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=73661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=73661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}